APA Alıntı

Dennis, M., Culligan, D., Karamitros, D., Vyas, P., Johnson, P., Russell, N., . . . Bowen, D. (2013). Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities(). Elsevier.

Chicago Stili Alıntı

Dennis, M., et al. Lenalidomide Monotherapy and in Combination With Cytarabine, Daunorubicin and Etoposide for High-risk Myelodysplasia and Acute Myeloid Leukaemia With Chromosome 5 Abnormalities(). Elsevier, 2013.

MLA Alıntı

Dennis, M., et al. Lenalidomide Monotherapy and in Combination With Cytarabine, Daunorubicin and Etoposide for High-risk Myelodysplasia and Acute Myeloid Leukaemia With Chromosome 5 Abnormalities(). Elsevier, 2013.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..